The estimated Net Worth of Adrienne L Graves is at least $1.36 Milion dollars as of 11 May 2023. Adrienne Graves owns over 14,588 units of IVERIC bio Inc stock worth over $882,416 and over the last 12 years he sold ISEE stock worth over $392,697. In addition, he makes $87,658 as Lead Independent Director at IVERIC bio Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Adrienne Graves ISEE stock SEC Form 4 insiders trading
Adrienne has made over 4 trades of the IVERIC bio Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 14,588 units of ISEE stock worth $582,791 on 11 May 2023.
The largest trade he's ever made was exercising 20,000 units of IVERIC bio Inc stock on 8 February 2017 worth over $257,400. On average, Adrienne trades about 2,152 units every 128 days since 2012. As of 11 May 2023 he still owns at least 22,088 units of IVERIC bio Inc stock.
You can see the complete history of Adrienne Graves stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Adrienne Graves biography
Dr. Adrienne L. Graves Ph.D. serves as Lead Independent Director of the Company. She has served as a member of our board of directors since December 2018. From 1995 to 2010, Dr. Graves worked at Santen, Inc., the United States subsidiary of a Japanese publicly traded pharmaceutical company, where Dr. Graves served as senior vice president of worldwide clinical development (United States, Europe and Japan) for seven years and chief executive officer and president for eight years. Prior to Santen, Dr. Graves served in various roles of increasing responsibility at Alcon for nine years. Dr. Graves currently serves on the boards of directors of Akorn Inc., Greenbrook TMS Inc., NicOx, S.A. and Oxurion NV, and previously served on the board of directors of TearLab Corporation, all of which are publicly traded biotechnology or pharmaceutical companies. Dr. Graves received an A.B. in psychology from Brown University and a Ph.D. in psychobiology from the University of Michigan, and completed a postdoctoral fellowship in visual neuroscience at the University of Paris. Graves is qualified to serve on our board of directors because of her strong background in ophthalmology, her extensive experience in pharmaceutical development and commercialization, and her service on the boards of directors of other life sciences companies.
What is the salary of Adrienne Graves?
As the Lead Independent Director of IVERIC bio Inc, the total compensation of Adrienne Graves at IVERIC bio Inc is $87,658. There are 13 executives at IVERIC bio Inc getting paid more, with Glenn Sblendorio having the highest compensation of $2,462,150.
How old is Adrienne Graves?
Adrienne Graves is 66, he's been the Lead Independent Director of IVERIC bio Inc since 2019. There are 1 older and 13 younger executives at IVERIC bio Inc. The oldest executive at IVERIC bio Inc is Calvin Roberts, 67, who is the Independent Director.
What's Adrienne Graves's mailing address?
Adrienne's mailing address filed with the SEC is C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD, MA, 01730.
Insiders trading at IVERIC bio Inc
Over the last 6 years, insiders at IVERIC bio Inc have traded over $8,677,595 worth of IVERIC bio Inc stock and bought 130,569 units worth $624,325 . The most active insiders traders include Glenn Sblendorio, Venture Capital Iv, L.P.Ver... a Keith Westby. On average, IVERIC bio Inc executives and independent directors trade stock every 15 days with the average trade being worth of $848,338. The most recent stock trade was executed by Keith Westby on 3 July 2023, trading 20,000 units of ISEE stock currently worth $58,800.
What does IVERIC bio Inc do?
we are a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (amd).
What does IVERIC bio Inc's logo look like?
Complete history of Adrienne Graves stock trades at Ocular Therapeutix Inc, IVERIC bio Inc a Harrow Health
IVERIC bio Inc executives and stock owners
IVERIC bio Inc executives and other stock owners filed with the SEC include:
-
Glenn Sblendorio,
President, Chief Executive Officer, Director -
David Guyer,
Executive Chairman of the Board -
Anthony S. Gibney,
Exec. VP and Chief Bus. & Strategy Officer -
David Carroll,
Chief Financial Officer, Senior Vice President, Treasurer -
Keith Westby,
Chief Operating Officer, Senior Vice President -
Glenn P. Sblendorio M.B.A.,
CEO & Director -
Dr. Pravin U. Dugel M.D.,
Pres -
David F. Carroll M.B.A.,
Sr. VP, CFO & Treasurer -
Christopher Paul Simms,
Sr. VP & Chief Commercial Officer -
David F. Carroll,
Sr. VP, CFO & Treasurer -
Keith Westby M.B.A.,
Sr. VP & COO -
Calvin Roberts,
Independent Director -
Jane Henderson,
Independent Director -
Adrienne Graves,
Lead Independent Director -
Axel Bolte,
Independent Director -
Kathy Galante,
Vice President, Investor Relations and Corporate Communications -
Mark Blumenkranz,
Director -
Abraham Scaria,
Chief Scientific Officer -
Evelyn Harrison,
Sr. VP & Chief Clinical Operations Officer -
Amy R. Sheehan,
Sr. VP & Chief HR Officer -
Todd D.C. Anderman,
Sr. VP, Gen. Counsel & Corp. Sec. -
Dr. Xiao-Ping Dai Ph.D.,
Chief Technical Officer -
Dr. Samir C. Patel,
Co-Founder and Consultant -
Christopher Paul Simms,
SVP, Chief Commercial Officer -
Christine Ann Miller,
Director -
David E Redlick,
Director -
Venture Capital Iv, L.P.Ver...,
-
Anthony S Gibney,
EVP, Chief Business Officer -
Pravin Dugel,
President